WO2001057184A3 - Use of platelet activity modulators for inhibiting complement activation - Google Patents

Use of platelet activity modulators for inhibiting complement activation Download PDF

Info

Publication number
WO2001057184A3
WO2001057184A3 PCT/US2001/003296 US0103296W WO0157184A3 WO 2001057184 A3 WO2001057184 A3 WO 2001057184A3 US 0103296 W US0103296 W US 0103296W WO 0157184 A3 WO0157184 A3 WO 0157184A3
Authority
WO
WIPO (PCT)
Prior art keywords
complement activation
platelet activity
inhibiting complement
modulator
warm
Prior art date
Application number
PCT/US2001/003296
Other languages
French (fr)
Other versions
WO2001057184A2 (en
Inventor
Richard N Pierson Iii
George L Zorn Iii
Todd D Giorgio
Agnes M Azimzadeh
Simon Robson
Original Assignee
Univ Vanderbilt
Beth Israel Hospital
Simon Robson
Richard N Pierson Iii
George L Zorn Iii
Todd D Giorgio
Agnes M Azimzadeh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Vanderbilt, Beth Israel Hospital, Simon Robson, Richard N Pierson Iii, George L Zorn Iii, Todd D Giorgio, Agnes M Azimzadeh filed Critical Univ Vanderbilt
Priority to AU2001234730A priority Critical patent/AU2001234730A1/en
Publication of WO2001057184A2 publication Critical patent/WO2001057184A2/en
Publication of WO2001057184A3 publication Critical patent/WO2001057184A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A61K38/58—Protease inhibitors from animals; from humans from leeches, e.g. hirudin, eglin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/22—Urine; Urinary tract, e.g. kidney or bladder; Intraglomerular mesangial cells; Renal mesenchymal cells; Adrenal gland
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/42—Respiratory system, e.g. lungs, bronchi or lung cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2848—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere

Abstract

A method of inhibiting complement activation, particularly by a transplanted tissue, in a warm-blooded vertebrate. The method includes administering a therapeutically effective amount of a platelet activity modulator to a warm-blooded vertebrate before, during or after a tissue is transplanted to the warm-blooded vertebrate, whereby complement activation by the transplanted tissue is inhibited. The platelet activity modulator can include a combination of a GPIb modulator and a GPIIb/GPIIIa modulator.
PCT/US2001/003296 2000-02-01 2001-02-01 Use of platelet activity modulators for inhibiting complement activation WO2001057184A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001234730A AU2001234730A1 (en) 2000-02-01 2001-02-01 Method for inhibiting complement activation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17954300P 2000-02-01 2000-02-01
US60/179,543 2000-02-01

Publications (2)

Publication Number Publication Date
WO2001057184A2 WO2001057184A2 (en) 2001-08-09
WO2001057184A3 true WO2001057184A3 (en) 2002-04-25

Family

ID=22657027

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/003296 WO2001057184A2 (en) 2000-02-01 2001-02-01 Use of platelet activity modulators for inhibiting complement activation

Country Status (3)

Country Link
US (2) US6538028B1 (en)
AU (1) AU2001234730A1 (en)
WO (1) WO2001057184A2 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001234730A1 (en) * 2000-02-01 2001-08-14 Beth Israel Deaconess Medical Center Method for inhibiting complement activation
US6716962B2 (en) * 2000-07-17 2004-04-06 Micrologix Biotech Inc. Extractive purification of lipopeptide antibiotics
US20040244062A1 (en) * 2003-06-02 2004-12-02 Crittenden Jill R. Use of protein inhibitors as antithrombotic agents
US7141544B2 (en) * 2003-10-10 2006-11-28 Baxter International, Inc. Stabilization of pharmaceutical protein formulations with small peptides
EP2338511A3 (en) * 2004-05-14 2012-07-25 Alexion Pharmaceuticals, Inc. Prolongation of survival of an allograft by inhibiting complement activity
US20070196367A1 (en) * 2006-02-22 2007-08-23 Valentin Dinu Methods of preventing and treating Alzheimer's disease, age related macular degeneration and other diseases involving extra-cellular debris through the inhibition of the complement system
AU2007224250B2 (en) * 2006-03-02 2012-05-03 Alexion Pharmaceuticals, Inc. Prolongation of survival of an allograft by inhibiting complement activity
DK2379066T3 (en) 2008-09-16 2014-06-30 Imunek Farma Ilaç Sanayi Ve Ticaret A S APPLICATION OF OPIOID ANTAGONISTS FOR THE PREPARATION OF A MEDICINE FOR THE TREATMENT OF RETAINED DEGENERY DISEASES
WO2011040894A1 (en) * 2009-10-01 2011-04-07 Mustafa Nevzat Ilaç Sanayii A.Ş. Topical compositions of opioid antagonists and methods for treating skin conditions therewith
TR201002473A2 (en) 2010-03-31 2011-09-21 Mustafa Nevzat �La� Sanay�� A.�. A method of treating herpes zoster disease using an opiate receptor antagonist.
US10588879B2 (en) 2011-08-01 2020-03-17 Aurin Biotech Inc. Treatment of age-related macular degeneration
US10966945B2 (en) 2011-08-01 2021-04-06 Aurin Biotech Inc. Selective inhibition of the membrane attack complex of complement by low molecular weight components of the aurin tricarboxylic synthetic complex
JP2015522060A (en) * 2012-07-13 2015-08-03 アウリン バイオテック インコーポレイテッド Selective inhibition of complement membrane attack complex and C3 convertase by low molecular weight components of aurintricarboxylic acid synthesis complex
US8877808B2 (en) * 2012-12-06 2014-11-04 Aurin Biotech Inc. Protection against skin diseases by aurin tricarboxylic acid and its derivatives
US10004707B2 (en) 2014-04-15 2018-06-26 Aurin Biotech Inc. Method for treating cancer with low molecular weight components of aurin tricarboxylic acid complex
US11013750B2 (en) 2017-01-20 2021-05-25 Aurin Biotech Inc. Methods for treating and preventing nociceptive pain

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4007270A (en) * 1975-11-18 1977-02-08 American Cyanamid Company Complement inhibitors
EP0251134A2 (en) * 1986-06-26 1988-01-07 Yeda Research And Development Company, Ltd. Compositions for preventing graft rejection
DE4338793A1 (en) * 1993-11-12 1995-05-18 Froelich Juergen C L-arginine and analogues as platelet aggregation inhibitors
JPH07196650A (en) * 1993-12-28 1995-08-01 Dai Ichi Seiyaku Co Ltd Argatroban pharmaceutical preparation having action suppressing proliferation of smooth muscle cell

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4880788A (en) 1987-10-30 1989-11-14 Baylor College Of Medicine Method for preventing and treating thrombosis
US5135916A (en) 1989-06-12 1992-08-04 Oklahoma Medical Research Foundation Inhibition of complement mediated inflammatory response
US5573940A (en) 1989-06-12 1996-11-12 Oklahoma Medical Research Foundation Cells expressing high levels of CD59
US5589582A (en) 1992-10-27 1996-12-31 Biotransplant, Inc. Polynucleotides en coding porcine cytokines
US5434185A (en) 1993-05-17 1995-07-18 The University Of Kentucky Research Foundation Method for inhibiting angiogenesis with aurintricarboxylic acid, its analogues or salts
US5891645A (en) 1994-06-01 1999-04-06 Alexion Pharmaceuticals, Inc. Porcine E-selectin
US5679345A (en) * 1994-06-02 1997-10-21 The Johns Hopkins University Method for preventing complement-dependent rejection of organ or tissue transplants
AU2001234730A1 (en) * 2000-02-01 2001-08-14 Beth Israel Deaconess Medical Center Method for inhibiting complement activation

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4007270A (en) * 1975-11-18 1977-02-08 American Cyanamid Company Complement inhibitors
EP0251134A2 (en) * 1986-06-26 1988-01-07 Yeda Research And Development Company, Ltd. Compositions for preventing graft rejection
DE4338793A1 (en) * 1993-11-12 1995-05-18 Froelich Juergen C L-arginine and analogues as platelet aggregation inhibitors
JPH07196650A (en) * 1993-12-28 1995-08-01 Dai Ichi Seiyaku Co Ltd Argatroban pharmaceutical preparation having action suppressing proliferation of smooth muscle cell

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BACH F H ET AL: "Delayed xenograft rejection", IMMUNOLOGY TODAY, ELSEVIER PUBLICATIONS, CAMBRIDGE, GB, vol. 17, no. 8, 1 August 1996 (1996-08-01), pages 379 - 384, XP004034598, ISSN: 0167-5699 *
DORLING A ET AL: "CLINICAL XENOTRANSPLANTATION OF SOLID ORGANS", LANCET THE, LANCET LIMITED. LONDON, GB, vol. 349, no. 9055, 22 March 1997 (1997-03-22), pages 867 - 871, XP002074455, ISSN: 0140-6736 *
EKRE H-P T: "INHIBITION OF HUMAN AND GUINEA PIG COMPLEMENT BY HEPARIN FRACTIONS DIFFERING IN AFFINITY FOR ANTITHROMBIN III OR IN AVERAGE MOLECULAR WEIGHT", INTERNATIONAL JOURNAL OF IMMUNOPHARMACOLOGY, ELMSFORD,NY, US, vol. 7, no. 2, 1985, pages 271 - 275,277-28, XP000106593, ISSN: 0192-0561 *
HOELSCHERMANN HANS ET AL: "Evaluation of recombinant hirudin in the prevention of experimental cardiac transplant vasculopathy.", CIRCULATION, vol. 110, no. 18 SUPPL., 2 November 1999 (1999-11-02), 72nd Scientific Sessions of the American Heart Association;Atlanta, Georgia, USA; November 7-10, 1999, pages I.682, XP001026570, ISSN: 0009-7322 *
PATENT ABSTRACTS OF JAPAN vol. 1995, no. 11 26 December 1995 (1995-12-26) *

Also Published As

Publication number Publication date
US20030144358A1 (en) 2003-07-31
WO2001057184A2 (en) 2001-08-09
US6538028B1 (en) 2003-03-25
AU2001234730A1 (en) 2001-08-14

Similar Documents

Publication Publication Date Title
WO2001057184A3 (en) Use of platelet activity modulators for inhibiting complement activation
ATE238744T1 (en) DENTAL NAPPY WITH ADHESIVE CONTAINING PERFUME MICRO CAPSULES
HK1069534A1 (en)
WO2000038665A3 (en) Use of an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
WO2001007067A3 (en) Solutions and methods for inhibition of pain, inflammation and cartilage degradation
UY26693A1 (en) A PHARMACEUTICAL COMPOSITION AND PROCEDURE FOR THE TREATMENT OF DISEASES OF COGNITIVE DYSFUNCTION IN A MAMMAL
WO2001062236A3 (en) New drug combinations comprising a norepinephrine reuptake inhibitor and an antimuscarinic agent
WO2002005800A8 (en) Compositions for sustained release of analgesic agents, and methods of making and using the same
WO2000054759A3 (en) Lxr modulators
AU2307999A (en) Muscarinic agents and use thereof to treat glaucoma, myopia and various other conditions
AU5905400A (en) Methods and compositions for delivery and retention of active agents to lymph nodes
BRPI0017528B8 (en) use of a composition containing ketotifen salt
WO2001078653A3 (en) Graft rejection inhibition with ccr2 inhibitors
IL152450A (en) Compounds and compositions for use in treating tnf-?? mediated conditions
CO5280202A1 (en) TREATMENT METHODS AND TRAFFIC METHODS OF PHARMACOS
GB9914616D0 (en) Attachment surface
WO2003008005A3 (en) Catheter and implants for the delivery of therapeutic agents to tissues
WO2000025745A3 (en) Irrigation solution and method for inhibition of pain and inflammation
AU2307899A (en) Muscarinic agents and use thereof to treat glaucoma, myopia and various other conditions
WO2002100432A8 (en) Methods for the modulation of il-13
MX9701606A (en) Combination therapy to prevent bone loss- progesterone and strogen.
PT1186302E (en) COMPOSITION FOR MAKING EYE TREATMENT FOR TOPIC ADMINISTRATION
ATE371446T1 (en) COMPOSITIONS FOR PREVENTING ADHESION
CO5070608A1 (en) METHOD FOR INCREASING THE PERMEABILITY OF THE HUMAN CORNEE FABRIC
WO2000074667A3 (en) Compositions active in telomere damage comprising a taxane and telomerase inhibitor

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP